Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J., Siegel, David, De Vos, Filip, Rasmussen, Erik, Henary, Haby A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211202/
https://www.ncbi.nlm.nih.gov/pubmed/31359240
http://dx.doi.org/10.1007/s10637-019-00840-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211202/
https://www.ncbi.nlm.nih.gov/pubmed/31359240
http://dx.doi.org/10.1007/s10637-019-00840-1

Ejemplares similares